Gilead Sciences Newswire

Comprehensive Real-Time News Feed for Gilead Sciences.

Results 1 - 20 of 818 in Gilead Sciences

  1. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    3 hrs ago | Business Wire

    )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2014 financial results will be released on Tuesday, October 28, at 4:05 p.m. Easter... )--Hyatt announces the groundbreaking for the fourth hotel in Puerto Rico. The ...

    Comment?

  2. My view: New treatment can cure Hepatitis CRead the original story w/Photo

    4 hrs ago | Deseret News

    ... of America's Health Insurance Plans, has been particularly accusatory, suggesting that Sovaldi's developer, Gilead Sciences Inc., has engaged in " 'whatever you can get away with' pricing." She's also claimed Sovaldi's high cost "will blow up family ...

    Comment?

  3. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    6 hrs ago | Business Wire

    Eck, 55, is currently the Chief O... )--The Board of Directors of McKesson Corporation today declared a regular dividend of twenty-four cents per share on Common Stock. The dividend will be paya... )--Gilead Sciences, Inc. announced today that its third quarter 2014 financial results will be released on Tuesday, October 28, at 4:05 p.m. Easter... )--Hyatt announces the groundbreaking for the fourth hotel in Puerto Rico.

    Comment?

  4. Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014Read the original story

    12 hrs ago | Business Wire

    )--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2014 financial results will be released on Tuesday, October 28, at 4:05 p.m. Eastern Time. At 4:30 p.m. Eastern Time, Gilead's management will host a conference call to ...

    Comment?

  5. Gilead Sciences: Pricing, Politics And ProfitsRead the original story w/Photo

    14 hrs ago | Seeking Alpha

    The other day I was rifling through the comments on one of my previous articles on Gilead Sciences , and a commenter requested an article about the politics surrounding Gilead's pricing of its Hep C drugs Sovaldi, and more recently, Harvoni. So, I began going through various articles, news reports and company statements focused on the uproar on pricing.

    Comment?

  6. Few California inmates with hepatitis C get costly SovaldiRead the original story w/Photo

    18 hrs ago | Medical News

    ... that can cure most patients in an unprecedented amount of time. In California's prisons, the drug, made by Gilead Sciences of Foster City, is being given to less than 1 percent of the 17,000 inmates with the virus. Sovaldi could wipe out what has ...

    Comment?

  7. Gilead Sciences (GILD): Clear The Dockets And Settle With Merck AlreadyRead the original story w/Photo

    19 hrs ago | Seeking Alpha

    Settling the patent cases with Merck would help secure Sovaldi/Harvoni worldwide for the long term and remove a nagging uncertainty. On November 21, 2011, Gilead Sciences announced the acquisition of Pharmasset for $11B.

    Comment?

  8. Gilead Sciences, Inc.'s $1,000-A-Pill Hepatitis C Drug May Make Financial Sense For PrisonsRead the original story

    23 hrs ago | BioSpace

    Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers. Sovaldi's $1,000-a-pill price - or $84,000 for a 12-week course of treatments - has been criticized by pharmacy benefits manager Express Scripts and others for potentially breaking private and public insurance programs.

    Comment?

  9. Gilead Sciences, Inc. To Create More Than 80 Jobs With $50 Million ExpansionRead the original story

    23 hrs ago | BioSpace

    U.S. biotech giant Gilead Sciences is expanding its presence in Edmonton. The Foster City, Calif.-based company said it has broken ground on a second research and development lab in northeast Edmonton's Eco Industrial Park.

    Comment?

  10. Gilead's $1,000-a-pill hepatitis C drug may make financial sense for prisonsRead the original story w/Photo

    Yesterday | Business Journal

    Sovaldi's $1,000-a-pill price has grabbed headlines, but a new study suggests it may actually be cost effective for prison systems. Pricey new hepatitis C drugs, such as Gilead Sciences Inc.'s Sovaldi, may make financial sense to give to give to prisoners, one of the main groups infected with the liver-damaging virus, according to a team of Stanford University researchers.

    Comment?

  11. Gilead Sciences announces $50-million Edmonton expansionRead the original story w/Photo

    Yesterday | Edmonton Journal

    ... to new product launches for the treatment of hepatitis C, HIV-AIDS and oncology, Gilead said in a release. "Gilead Sciences is proud of the role of the Alberta site in developing innovative medical therapies for some of today's most challenging ...

    Comment?

  12. Read the original story w/Photo

    Yesterday | SFGate

    In San Francisco's jails, no inmates with hepatitis C are receiving Sovaldi, the breakthrough pill that can cure most patients in an unprecedented amount of time. In California's prisons, the drug, made by Gilead Sciences of Foster City, is being given to less than 1 percent of the 17,000 inmates with the virus.

    Comment?

  13. Biotech giant Gilead Sciences expanding in Edmonton with second city labRead the original story

    Monday | Edmonton Journal

    Gilead Sciences, one of the largest biotech companies in the U.S. with a market cap of more than $150 billion US, has broken ground on a new $50 million lab facility in northeast Edmonton, the company says. The 44,000-square-foot lab is the second Gilead lab in Edmonton, where the Foster City, Calif.-based company already employs 300 staff.

    Comment?

  14. Gilead: Stage Set For RallyRead the original story w/Photo

    Monday | Seeking Alpha

    The dip in the shares of Gilead Sciences last week presented a good opportunity to add additional shares in this cheap biotech juggernaut. The company has several positive catalysts on the horizon that should power the next stage of the stock's rally.

    Comment?

  15. Recent Study: Arrhythmias - Pipeline Review, H2 2014Read the original story

    Monday | PR-inside.com

    ... projects and understanding the factors that drove them from pipeline Companies Mentioned in this Report: Gilead Sciences, Inc., Orion Oyj, SciFluor Life Sciences, LLC, Nyken BV About Global Markets Direct Global Markets Direct is a leading provider ...

    Comment?

  16. Perrigo CEO Constructs "Five Pillars" For SuccessRead the original story w/Photo

    Friday Oct 17 | Investor's Business Daily

    Trained as a pharmacist, Joseph Papa learned to scrutinize science when making a decision. Earning his bachelor's degree in pharmacy taught him to use Socratic questions to dig for answers.

    Comment?

  17. A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead NowRead the original story w/Photo

    Friday Oct 17 | Seeking Alpha

    ... still looks favorable. The stock trades at just above 11x 2014 earnings and 10x 2015 forward earnings. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes medicines for the treatment of life-threatening ...

    Comment?

  18. Health Canada Issues Notice Of Compliance For Gilead Sciences, Inc.'s ...Read the original story

    Friday Oct 17 | BioSpace

    /CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single table regimen for the treatment of chronic hepatitis C ...

    Comment?

  19. Health Canada Issues Notice of Compliance for Gilead's Harvonia ...Read the original story w/Photo

    Thursday Oct 16 | Information Technology

    Gilead Sciences, Inc. today announced that Health Canada has issued a Notice of Compliance for Harvoni , the first once-daily single table regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, granted marketing authorization under the tradename Sovaldi in December 2013.

    Comment?

  20. Buy These Five Beaten-Down Biotech Stocks, Nomura SaysRead the original story w/Photo

    Thursday Oct 16 | Barron's

    Yes, say the folks at Nomura , who recommend buying Celgene , Receptos , Gilead Sciences , Neurocrine Biosciences , and Alexion Pharmaceuticals , in that order. Analyst M. Ian Somaiya and team explain why: October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the S&P 500 in 14 out the last 20 years.

    Comment?